Contents:

Executive Summary Profiled Companies Overcoming Portfolio Management Challenges: Five Principles for Success Streamlining the Portfolio Management Team Portfolio Management Structure Portfolio Management Resources and Support Portfolio Management Tools Implementing the Portfolio Management Strategy Portfolio Management Activities & Timing Portfolio Management Criteria and Data Analysis Developing a Licensing Strategy Select Companies’ Product Portfolio Profiles Alizyme AstraZeneca Avant Immunotherapeutics Cardiome Pharma Human Genome Sciences Johnson & Johnson Novartis Roche Serono TAP Pharmaceuticals Streamlining the Portfolio Management Team Portfolio Management Structure Figure 1.1 : Dedicated Portfolio Management Groups Figure 1.2 : Dedicated Portfolio Management Groups: Global-Level Figure 1.3 : Dedicated Portfolio Management Groups: Affiliate-Level Figure 1.4 : Dedicated Portfolio Management Groups: Small Companies Figure 1.5 : Dedicated Portfolio Management Groups: Mid-Sized Companies Figure 1.6 : Dedicated Portfolio Management Groups: Large Companies Figure 1.7: Portfolio Management Group Structure Figure 1.8: Portfolio Management Group Structure: Global-Level Figure 1.9: Portfolio Management Group Structure: Affiliate-Level Figure 1.10: Portfolio Management Group Structure: Small Companies Figure 1.11: Portfolio Management Group Structure: Mid-Sized Companies Figure 1.12: Portfolio Management Group Structure: Large Companies Figure 1.13: Reporting Relationships in Portfolio Management Figure 1.14: Reporting Relationships in Portfolio Management: Global-Level Figure 1.15: Reporting Relationships in Portfolio Management: Affiliate-Level Figure 1.16: Reporting Relationships in Portfolio Management: Global vs. Affiliate Figure 1.17: Reporting Relationships in Portfolio Management: Company Size Comparison Figure 1.18: Reporting Relationships in Portfolio Management: Small Companies Figure 1.19: Reporting Relationships in Portfolio Management: Mid-Sized Companies Figure 1.20: Reporting Relationships in Portfolio Management: Large Companies Portfolio Management Resources and Support Figure 1.21: Percent of Participants Satisfied with Portfolio Management Resources Figure 1.22: Percent of Global-Level Participants Satisfied with Portfolio Management Resources Figure 1.23: Percent of Affiliate-Level Participants Satisfied with Portfolio Management Resources Figure 1.24: Percent of Participants Satisfied with Portfolio Management Streamlining the Portfolio Management Team Resources by Company Size Figure 1.25: Portfolio Management Budgets by Company Figure 1.26: Portfolio Management Budgets Based on Number of Investigational Drugs Figure 1.27: Portfolio Management Budgets Based on Number of Marketed Drugs Figure 1.28: Percent Allocation for Portfolio Investments Figure 1.29: Percent Allocation for Global and Affiliate Portfolio Investments Figure 1.30: Percent Allocation for Portfolio Investments by Company Figure 1.31: Portfolio Management Staffing per Company Figure 1.32: Average Staffing by Company Size Figure 1.33: Average Portfolio Management Staffing: Global vs. Affiliate Figure 1.34: Product Investment Rankings: Global vs. Affiliate Figure 1.35: Product Investment Rankings by Company Size Figure 1.36: Factors Influencing Increased Portfolio Investments Figure 1.37: Factors Influencing Increased Portfolio Investments: Global vs. Affiliate Figure 1.38: Factors Influencing Increased Portfolio Investments by Company Size Figure 1.38: Factors Influencing Increased Portfolio Investments by Company Size Figure 1.40: Factors Influencing Decreased Portfolio Investments: Global vs. Affiliate Figure 1.41: Factors Influencing Decreased Portfolio Investments by Company Size Portfolio Management Tools Figure 1.42: Tools Used to Facilitate Portfolio Management Activities Figure 1.43: Global-Level Portfolio Management Tools Figure 1.44: Affiliate-Level Portfolio Management Tools Figure 1.45: Portfolio Management Tools Comparison by Company Size Figure 1.46: Small Companies’ Portfolio Management Tools Figure 1.47: Mid-Sized Companies’ Portfolio Management Tools Figure 1.48: Large Companies’ Portfolio Management Tools Implementing the Portfolio Management Strategy Portfolio Management Activities & Timing Figure 2.1: Departments Participating in Portfolio Management Activities Figure 2.2: Global Departments Participating in Portfolio Management Activities Figure 2.3: Affiliate-Level Departments Participating in Portfolio Management Activities Figure 2.4: Participation in Portfolio Management Activities: Company Size Comparison Figure 2.5: Large Companies’ Departments Participating in Portfolio Management Activities Figure 2.6: Mid-Sized Companies’ Departments Participating in Portfolio Management Activities Figure 2.7: Small Companies’ Departments Participating in Portfolio Management Activities Figure 2.8: Individuals Participating in Portfolio Management Activities Figure 2.9: Individuals Participating in Portfolio Management Activities: Global-Level Figure 2.10: Individuals Participating in Portfolio Management Activities: Affiliate-Level Figure 2.11: Individuals Participating in Portfolio Management Activities: Small Companies Figure 2.12 Individuals Participating in Portfolio Management Activities: Mid-Sized Companies Figure 2.13: Individuals Participating in Portfolio Management Activities: Large Companies Figure 2.14: Portfolio Management Timing: Initiate Activities Figure 2.15: Portfolio Management Timing: Global-Level Initiation Figure 2.16: Portfolio Management Timing: Affiliate-Level Initiation Figure 2.17: Portfolio Management Timing: Small Companies’ Initiation Figure 2.18: Portfolio Management Timing: Mid-Sized Companies’ Initiation Figure 2.20: Portfolio Management Meetings Figure 2.21: Portfolio Management Meetings: Global-Level Figure 2.22: Portfolio Management Meetings: Affiliate-Level Figure 2.23: Portfolio Management Meetings: Small Companies Figure 2.24: Portfolio Management Meetings: Mid-Sized Companies Figure 2.25: Portfolio Management Meetings: Large Companies Figure 2.26: Portfolio Management Time Commitment Figure 2.27: Portfolio Management Time Commitment: Global-Level Figure 2.28: Portfolio Management Time Commitment: Affiliate-Level Figure 2.29: Portfolio Management Time Commitment: Small Companies Figure 2.30: Portfolio Management Time Commitment: Mid-Sized Companies Figure 2.31: Portfolio Management Time Commitment: Large Companies Figure 2.32: Portfolio Management Success Figure 2.34: Portfolio Management Success: Affiliate-Level Figure 2.33: Portfolio Management Success: Global-Level Figure 2.35: Portfolio Management Success: Small Companies Figure 2.36: Portfolio Management Success: Mid-Sized Companies Figure 2.37: Portfolio Management Success: Large Companies Figure 2.38: Portfolio Management’s Greatest Barriers to Success Figure 2.39: Portfolio Management’s Greatest Barriers to Success: Global-Level Figure 2.40: Portfolio Management’s Greatest Barriers to Success: Affiliate-Leve Figure 2.41: Portfolio Management’s Greatest Barriers to Success: Small Companies Figure 2.42: Portfolio Management’s Greatest Barriers to Success: Mid-Sized Companies Figure 2.43: Portfolio Management’s Greatest Barriers to Success: Large Companies Developing a Licensing Strategy Figure 2.44: Strategy Behind Inbound Deals Figure 2.45: Strategy Behind Outbound Deals Figure 2.46: Licensing Enters the Pipeline Figure 2.47: Number of Inbound Deals Per Company Per Year Figure 2.48: Number of Outbound Deals Per Company Per Year Figure 2.49: Number of Global Inbound Deals Per Company Per Year Figure 2.50: Number of Global Outbound Deals Per Company Per Year Figure 2.51: Number of Affiliate Inbound Deals Per Company Per Year Figure 2.52: Number of Affiliate Outbound Deals Per Company Per Year Figure 2.53: Cross-Functional Deal Making Figure 2.54: Company D’s Licensing Strategy Structure

Companies Mentioned

Companies Profiled in this Report: Alizyme Amarin SA Amgen Astellas Pharmaceuticals Avant Immunotherapeutics Bayer Boehringer-Ingelheim Cardiome Pharma EKR Therapeutics Eli Lilly Genesis R&D HUB, Inc. Human Genome Science Johnson & Johnson Merck & Co. Merck KGaA Novartis Organon Pharmexa Roche Schering-Plough Serono TAP Pharmaceuticals TEVA Wyeth